» Articles » PMID: 35454785

The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic Against Ovarian and Endometrial Cancers

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Apr 23
PMID 35454785
Authors
Affiliations
Soon will be listed here.
Abstract

Sortilin (SORT1) receptor-mediated endocytosis functions were exploited for this new approach for effective and safe treatments of gynecological cancers. Here, high expression of SORT1 was found in >75% of the clinically annotated ovarian and endometrial tumors analyzed by immunohistochemistry. Therefore, the anticancer properties of the peptide-drug conjugate TH1902, a peptide that targets SORT1 and which is linked to docetaxel molecules, were investigated both in vitro using ovarian and endometrial cancer cell cultures and in vivo using xenograft models. In vitro, TH1902 inhibited cell proliferation and triggered higher SORT1-dependent cell apoptosis than unconjugated docetaxel did in ES-2 and SKOV3 ovarian cancer cell lines. The uptake of the Alexa488-TH19P01 peptide from TH1902 was reduced upon siRNA-mediated silencing of SORT1. In vivo, weekly administration of TH1902 showed better tolerability compared to equivalent docetaxel doses and inhibited tumor growth in ovarian and endometrial xenograft mice models. TH1902 as a single agent inhibited ovarian tumor growth more than either of the unconjugated taxanes or carboplatin. Furthermore, TH1902 combination with carboplatin also demonstrated better efficacy when compared to both taxanes-carboplatin combinations. Overall, TH1902 shows better in vivo efficacy, compared to that of docetaxel and even paclitaxel, against SORT1-positive ovarian and endometrial cancers and could be safely combined with carboplatin.

Citing Articles

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.

PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.


Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers.

Bertrand N, Mougel R, Riley G, Bruand M, Gauchotte G, Agopiantz M Int J Mol Sci. 2024; 25(21).

PMID: 39519199 PMC: 11546766. DOI: 10.3390/ijms252111648.


Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems.

Lin Q, Li J, Abudousalamu Z, Sun Y, Xue M, Yao L Int J Nanomedicine. 2024; 19:9351-9370.

PMID: 39282574 PMC: 11401532. DOI: 10.2147/IJN.S478313.


Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.

Kathad U, Biyani N, Peru Y Colon De Portugal R, Zhou J, Kochat H, Bhatia K PLoS One. 2024; 19(8):e0308604.

PMID: 39186767 PMC: 11346940. DOI: 10.1371/journal.pone.0308604.


An enhanced intracellular delivery platform based on a distant diphtheria toxin homolog that evades pre-existing antitoxin antibodies.

Gill S, Sugiman-Marangos S, Beilhartz G, Mei E, Taipale M, Melnyk R EMBO Mol Med. 2024; 16(10):2638-2651.

PMID: 39160301 PMC: 11473700. DOI: 10.1038/s44321-024-00116-z.


References
1.
Farahi L, Ghaemimanesh F, Milani S, Razavi S, Akhondi M, Rabbani H . Sortilin as a Novel Diagnostic and Therapeutic Biomarker in Chronic Lymphocytic Leukemia. Avicenna J Med Biotechnol. 2020; 11(4):270-276. PMC: 6925395. View

2.
Roselli S, Pundavela J, Demont Y, Faulkner S, Keene S, Attia J . Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion. Oncotarget. 2015; 6(12):10473-86. PMC: 4496368. DOI: 10.18632/oncotarget.3401. View

3.
Ghaemimanesh F, Ahmadian G, Talebi S, Zarnani A, Behmanesh M, Hemmati S . The effect of sortilin silencing on ovarian carcinoma cells. Avicenna J Med Biotechnol. 2014; 6(3):169-77. PMC: 4147104. View

4.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

5.
Moschetta M, Boussios S, Rassy E, Samartzis E, Funingana G, Uccello M . Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?. Ann Transl Med. 2021; 8(24):1710. PMC: 7812234. DOI: 10.21037/atm-20-1683. View